Recognizing and Managing Immune-Related Adverse Events in Endometrial Cancer

Dr. Thaker reviews the immune-related adverse event profile associated with checkpoint inhibitor therapy in endometrial cancer, describing the most commonly encountered toxicities in clinical practice, including hypothyroidism, hyperthyroidism, colitis, and arthralgias. She notes the particular challenge of distinguishing immune-mediated effects from age-related comorbidities in an older patient population and emphasizes that most toxicities are manageable with dose interruption, corticosteroids, or both. Dr. Thaker highlights the importance of proactive patient education—stressing that immune-related toxicities differ fundamentally from the side effect profile of cytotoxic chemotherapy and may present subtly—and describes her approach of encouraging patients to report any new or unusual symptoms promptly. Dr. Wenham closes the segment with a reflection on the broader clinical progress the field has made, noting that managing long-term treatment-related side effects is itself a marker of patients living longer.